173 related articles for article (PubMed ID: 36229873)
1. Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma.
Hölting TLB; Cidre-Aranaz F; Matzek D; Popper B; Jacobi SJ; Funk CM; Geyer FH; Li J; Piseddu I; Cadilha BL; Ledderose S; Zwilling J; Ohmura S; Anz D; Künkele A; Klauschen F; Grünewald TGP; Knott MML
Mol Cancer; 2022 Oct; 21(1):199. PubMed ID: 36229873
[TBL] [Abstract][Full Text] [Related]
2. Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma.
Wang S; Huo X; Yang Y; Mo Y; Kollipara RK; Kittler R
Cancer Lett; 2023 Jan; 552():215984. PubMed ID: 36330954
[TBL] [Abstract][Full Text] [Related]
3. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability.
He T; Surdez D; Rantala JK; Haapa-Paananen S; Ban J; Kauer M; Tomazou E; Fey V; Alonso J; Kovar H; Delattre O; Iljin K
Gene; 2017 Jan; 596():137-146. PubMed ID: 27760381
[TBL] [Abstract][Full Text] [Related]
4. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma.
Shimizu R; Tanaka M; Tsutsumi S; Aburatani H; Yamazaki Y; Homme M; Kitagawa Y; Nakamura T
Cancer Sci; 2018 Sep; 109(9):2907-2918. PubMed ID: 29945296
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
6. Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.
Knott MML; Hölting TLB; Ohmura S; Kirchner T; Cidre-Aranaz F; Grünewald TGP
Cancer Metastasis Rev; 2019 Dec; 38(4):625-642. PubMed ID: 31970591
[TBL] [Abstract][Full Text] [Related]
7. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.
Grohar PJ; Kim S; Rangel Rivera GO; Sen N; Haddock S; Harlow ML; Maloney NK; Zhu J; O'Neill M; Jones TL; Huppi K; Grandin M; Gehlhaus K; Klumpp-Thomas CA; Buehler E; Helman LJ; Martin SE; Caplen NJ
Cell Rep; 2016 Jan; 14(3):598-610. PubMed ID: 26776507
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting the oncogenic driver EWSR1::FLI1 in Ewing sarcoma through inhibition of the FACT complex.
Mo J; Tan K; Dong Y; Lu W; Liu F; Mei Y; Huang H; Zhao K; Lv Z; Ye Y; Tang Y
Oncogene; 2023 Jan; 42(1):11-25. PubMed ID: 36357572
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
[TBL] [Abstract][Full Text] [Related]
11. EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
Yasir M; Park J; Chun W
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894854
[TBL] [Abstract][Full Text] [Related]
12. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
14. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
15. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
17. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
[TBL] [Abstract][Full Text] [Related]
18. A Druggable Rheostat for Ewing Sarcoma?
Weiss KR; Bailey KM
Clin Cancer Res; 2022 Oct; 28(20):4360-4362. PubMed ID: 35921177
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
[TBL] [Abstract][Full Text] [Related]
20. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor.
Franzetti GA; Laud-Duval K; Bellanger D; Stern MH; Sastre-Garau X; Delattre O
Oncogene; 2013 Aug; 32(33):3915-21. PubMed ID: 22986530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]